278 related articles for article (PubMed ID: 36714582)
21. Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.
Bernard V; Lamothe S; Beau I; Guillou A; Martin A; Le Tissier P; Grattan D; Young J; Binart N
FASEB J; 2018 Sep; 32(9):4791-4797. PubMed ID: 29596024
[TBL] [Abstract][Full Text] [Related]
22. Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.
Leehy KA; Truong TH; Mauro LJ; Lange CA
J Steroid Biochem Mol Biol; 2018 Feb; 176():88-93. PubMed ID: 28442393
[TBL] [Abstract][Full Text] [Related]
23. Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor.
Dif F; Saunier E; Demeneix B; Kelly PA; Edery M
Endocrinology; 2001 Dec; 142(12):5286-93. PubMed ID: 11713228
[TBL] [Abstract][Full Text] [Related]
24. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
[TBL] [Abstract][Full Text] [Related]
25. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
26. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
Anderson MG; Zhang Q; Rodriguez LE; Hecquet CM; Donawho CK; Ansell PJ; Reilly EB
BMC Cancer; 2021 Jun; 21(1):681. PubMed ID: 34107902
[TBL] [Abstract][Full Text] [Related]
27. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R).
Zhang Y; Gc S; Patel SB; Liu Y; Paterson AJ; Kappes JC; Jiang J; Frank SJ
Mol Cell Endocrinol; 2019 Jul; 492():110445. PubMed ID: 31100495
[TBL] [Abstract][Full Text] [Related]
28. MICA-G129R: A bifunctional fusion protein increases PRLR-positive breast cancer cell death in co-culture with natural killer cells.
Ding H; Buzzard GW; Huang S; Sehorn MG; Marcus RK; Wei Y
PLoS One; 2021; 16(6):e0252662. PubMed ID: 34077462
[TBL] [Abstract][Full Text] [Related]
29. The many faces of prolactin in breast cancer.
Chen WY
Adv Exp Med Biol; 2015; 846():61-81. PubMed ID: 25472534
[TBL] [Abstract][Full Text] [Related]
30. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
31. Prolactin (PRL) and prolactin receptor (PRLR) genes and their role in poultry production traits.
Wilkanowska A; Mazurowski A; Mroczkowski S; Kokoszyński D
Folia Biol (Krakow); 2014; 62(1):1-8. PubMed ID: 24745142
[TBL] [Abstract][Full Text] [Related]
32. Connections between prolactin and ovarian cancer.
Alkharusi A; AlMuslahi A; AlBalushi N; AlAjmi R; AlRawahi S; AlFarqani A; Norstedt G; Zadjali F
PLoS One; 2021; 16(8):e0255701. PubMed ID: 34358244
[TBL] [Abstract][Full Text] [Related]
33. Defective prolactin signaling impairs pancreatic β-cell development during the perinatal period.
Auffret J; Freemark M; Carré N; Mathieu Y; Tourrel-Cuzin C; Lombès M; Movassat J; Binart N
Am J Physiol Endocrinol Metab; 2013 Nov; 305(10):E1309-18. PubMed ID: 24064341
[TBL] [Abstract][Full Text] [Related]
34. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
35. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.
Agarwal N; Machiels JP; Suárez C; Lewis N; Higgins M; Wisinski K; Awada A; Maur M; Stein M; Hwang A; Mosher R; Wasserman E; Wu G; Zhang H; Zieba R; Elmeliegy M
Oncologist; 2016 May; 21(5):535-6. PubMed ID: 27091421
[TBL] [Abstract][Full Text] [Related]
36. New mechanisms for PRLr action in breast cancer.
Clevenger CV; Gadd SL; Zheng J
Trends Endocrinol Metab; 2009 Jul; 20(5):223-9. PubMed ID: 19535262
[TBL] [Abstract][Full Text] [Related]
37. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
38. Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy.
López-Ozuna VM; Hachim IY; Hachim MY; Lebrun JJ; Ali S
Sci Rep; 2016 Aug; 6():30934. PubMed ID: 27480353
[TBL] [Abstract][Full Text] [Related]
39. The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers.
Ramírez-de-Arellano A; Villegas-Pineda JC; Hernández-Silva CD; Pereira-Suárez AL
Front Endocrinol (Lausanne); 2021; 12():747810. PubMed ID: 34745013
[TBL] [Abstract][Full Text] [Related]
40. Mammary gland-specific regulation of GNRH and GNRH-receptor gene expression is likely part of a local autoregulatory system in female vizcachas (Rodentia: Chinchillidae).
Corso MC; Cortasa SA; Schmidt AR; Proietto S; Inserra PIF; Fernández MO; Di Giorgio N; Lux-Lantos V; Vitullo AD; Dorfman VB; Halperin J
Gen Comp Endocrinol; 2020 Sep; 296():113518. PubMed ID: 32474048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
